As filed with the Securities and Exchange Commission on October 1, 2013
Registration No. 333-04839
Registration No. 333-34681
Registration No. 333-84113
Registration No. 333-60805
Registration No. 333-48146
Registration No. 333-64706
Registration No. 333-96895
Registration No. 333-110469
Registration No. 333-120324
Registration No. 333-126089
Registration No. 333-134567
Registration No. 333-143309
Registration No. 333-150928
Registration No. 333-159496
Registration No. 333-167209
Registration No. 333-181622
Registration No. 333-190496
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective
Amendment No. 1
To
FORM S-8 REGISTRATION STATEMENT NO. 333-126089
FORM S-8 REGISTRATION STATEMENT NO. 333-134567
FORM S-8 REGISTRATION STATEMENT NO. 333-143309
FORM S-8 REGISTRATION STATEMENT NO. 333-150928
FORM S-8 REGISTRATION STATEMENT NO. 333-159496
FORM S-8 REGISTRATION STATEMENT NO. 333-167209
FORM S-8 REGISTRATION STATEMENT NO. 333-181622
FORM S-8 REGISTRATION STATEMENT NO. 333-190496
Post-Effective Amendment No. 2
To
FORM S-8 REGISTRATION
STATEMENT NO. 333-04839
FORM S-8 REGISTRATION STATEMENT NO. 333-34681
FORM S-8 REGISTRATION STATEMENT NO. 333-84113
FORM S-8 REGISTRATION STATEMENT NO. 333-60805
FORM S-8 REGISTRATION STATEMENT NO. 333-48146
FORM S-8 REGISTRATION STATEMENT NO. 333-64706
FORM S-8 REGISTRATION STATEMENT NO. 333-96895
FORM S-8 REGISTRATION STATEMENT NO. 333-110469
FORM S-8 REGISTRATION STATEMENT NO. 333-120324
UNDER
THE
SECURITIES ACT OF 1933
ONYX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
94-3154463
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification Number)
|
249 East Grand Avenue
South San Francisco, CA 94080
(650) 266-0000
(Address,
including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
EMPLOYEE STOCK
PURCHASE PLAN, AS AMENDED
1996 EQUITY INCENTIVE PLAN, AS AMENDED
1996 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED
1996 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN
2005 EQUITY INCENTIVE PLAN, AS AMENDED
(Full title of the plan)
David J.
Scott, Esq.
Senior Vice President, General Counsel and Secretary
Onyx Pharmaceuticals, Inc.
c/o Amgen Inc.
One Amgen
Center Drive
Thousand Oaks, CA 91320-1799
(805) 447-1000
(Name,
address and telephone number of agent for service)
With a copy
to:
Francis J. Aquila, Esq.
Matthew G. Hurd, Esq.
Sarah P. Payne, Esq.
Sullivan & Cromwell LLP
125 Broad Street
New
York, NY 10004-2498
(212) 558-4000
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and
“smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
x
|
|
Accelerated filer
|
|
¨
|
|
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
EXPLANATORY NOTE
This Post-Effective Amendment relates to the following Registration Statements of Onyx Pharmaceuticals, Inc., a Delaware corporation
(“Onyx”) (collectively, the “Registration Statements”):
|
|
•
|
|
Registration Statement No. 333-04839, filed with the Securities and Exchange Commission (the “SEC”) on May 30, 1996, registering 1,594,587 shares of Onyx’s common stock, par value $0.001 per
share (“Shares”), under the Onyx 1996 Equity Incentive Plan, the Onyx 1996 Employee Stock Purchase Plan and the Onyx 1996 Non-Employee Directors’ Stock Option Plan;
|
|
|
•
|
|
Registration Statement No. 333-34681, filed with the SEC on August 29, 1997, registering 600,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-60805, filed with the SEC on August 6, 1998, registering 375,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended, and the Onyx 1996 Employee Stock Purchase Plan, as
amended;
|
|
|
•
|
|
Registration Statement No. 333-84113, filed with the SEC on July 30, 1999, registering 300,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-48146, filed with the SEC on October 18, 2000, registering 550,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended, the Onyx 1996 Employee Stock Purchase Plan, as
amended, and the Onyx 1996 Non-Employee Directors’ Stock Option Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-64706, filed with the SEC on July 6, 2001, registering 975,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended, and the Onyx 1996 Non-Employee Directors’ Stock
Option Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-96895, filed with the SEC on July 22, 2002, registering 475,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended, and the Onyx 1996 Employee Stock Purchase Plan, as
amended;
|
|
|
•
|
|
Registration Statement No. 333-110469, filed with the SEC on November 13, 2003, registering 700,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended, and the Onyx 1996 Non-Employee Directors’ Stock
Option Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-120324, filed with the SEC on November 9, 2004, registering 600,000 Shares under the Onyx 1996 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-126089, filed with the SEC on June 23, 2005, registering 3,990,000 Shares under the Onyx 2005 Equity Incentive Plan and covering 3,570,045 Shares previously registered under certain
of the Registration Statements under the Onyx 1996 Equity Incentive Plan, as amended, and the Onyx 1996 Non-Employee Directors’ Stock Option Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-134567, filed with the SEC on May 30, 2006, registering 75,000 Shares under the Onyx 1996 Employee Stock Purchase Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-143309, filed with the SEC on May 25, 2007, registering 2,100,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended, and the Onyx 1996 Employee Stock Purchase Plan, as
amended;
|
|
|
•
|
|
Registration Statement No. 333-150928, filed with the SEC on May 15, 2008, registering 3,100,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-159496, filed with the SEC on May 27, 2009, registering 2,000,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-167209, filed with the SEC on May 28, 2010, registering 3,000,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended;
|
|
|
•
|
|
Registration Statement No. 333-181622, filed with the SEC on May 23, 2012, registering 2,000,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended; and
|
|
|
•
|
|
Registration Statement No. 333-190496, filed with the SEC on August 9, 2013, registering 4,800,000 Shares under the Onyx 2005 Equity Incentive Plan, as amended, and the Onyx 1996 Employee Stock Purchase Plan, as
amended.
|
Onyx is filing this Post-Effective Amendment No. 1 or No. 2, as the case may be, to its Registration
Statements to withdraw and remove from registration the unissued and unsold securities issuable by Onyx pursuant to the above referenced Registration Statements.
Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 24, 2013, by and among Onyx, Amgen
Inc., a Delaware corporation (“Amgen”) and Arena Acquisition Company, a former Delaware corporation and wholly owned subsidiary of Amgen (“Merger Sub”), on October 1, 2013, Merger Sub merged with and into Onyx (the
“Merger”). Pursuant to the terms of the Merger Agreement, each Share of Onyx outstanding immediately prior to the effective time of the Merger ceased to be outstanding and (other than Shares then owned by Amgen, Onyx or any of their direct
or indirect wholly owned subsidiaries and
-2-
Shares that are held by stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive $125.00 in cash, without interest, less any applicable
withholding taxes. As a result of the Merger, Onyx became a wholly owned subsidiary of Amgen.
As a result of the consummation of the
transactions contemplated by the Merger Agreement, Onyx has terminated all offerings of its securities pursuant to the above referenced Registration Statements. In accordance with an undertaking made by Onyx in each of the Registration Statements to
remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, Onyx hereby removes and withdraws from registration all securities of Onyx registered pursuant to the Registration
Statements that remain unsold as of the date hereof.
-3-
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 1 or No. 2,
as the case may be, to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Thousand Oaks, State of California, on this October 1, 2013.
|
|
|
|
|
|
|
ONYX PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
|
/s/ David J. Scott
|
|
|
|
Name:
|
|
David J. Scott
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
No other person is required to sign this Post-Effective Amendment No. 1 or No. 2, as the case may be, to the
Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.
-4-
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Apr 2024 to May 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From May 2023 to May 2024
